The impact of the single exit price policy on a basket of generic medicines in South Africa, using a time series analysis from 1999 to 2014
- PMID: 31365534
- PMCID: PMC6668780
- DOI: 10.1371/journal.pone.0219690
The impact of the single exit price policy on a basket of generic medicines in South Africa, using a time series analysis from 1999 to 2014
Abstract
Background: Regulating pharmaceutical markets have become a key strategy by most governments in ensuring the availability and accessibility of quality medicines to its citizens. The South African government, when faced with high medicine prices, implemented the Single Exit Price (SEP) in 2004. This study assessed the impact of the of the Single Exit Price (SEP) regulation introduced in South Africa in 2004 on a basket of generic.
Method: Private sector price data of a basket of medicines (December 1999 to December 2014) was obtained from various price files (Pharmacy Software Vendors and Community Pharmacy). The price of the medicine was expressed in a single unit dose. The medicines investigated used the WHO/HAI methodology. The Interrupted Time-Series (ITS) model was used to estimate the change in slope and level of medicines investigated (50 originator and its available generics) before and after the policy change.
Results: Majority of the medicines analysed reflect a substantial decrease in medicine prices immediately after implementation of the pricing regulations as reflected in both the change in level and the change in slope using the interrupted time series analysis.
Discussion: This study indicates that the SEP regulation had an impact on medicine pricing in South Africa in both the short (immediately on the introduction) and long term (over the study period). Most medicines investigated showed a smaller yearly increase in price compared to before regulations.
Conclusion: This study provides evidence of the impact of medicine pricing intervention from a middle-income country, and useful lessons can be drawn by other developing countries looking at introducing medicine price controls.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures






Similar articles
-
Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis.BMC Health Serv Res. 2019 Aug 16;19(1):576. doi: 10.1186/s12913-019-4403-8. BMC Health Serv Res. 2019. PMID: 31419977 Free PMC article.
-
Pseudo-Generics in South Africa: A Price Comparison.Value Health Reg Issues. 2019 Sep;19:87-91. doi: 10.1016/j.vhri.2019.06.001. Epub 2019 Jul 26. Value Health Reg Issues. 2019. PMID: 31357098 Free PMC article.
-
Evaluating the impact of single exit pricing (SEP) on medicine product withdrawal from the private healthcare market in South Africa.S Afr Med J. 2021 Apr 30;111(5):444-447. doi: 10.7196/SAMJ.2021.v111i5.15297. S Afr Med J. 2021. PMID: 34852886
-
Impact of European pharmaceutical price regulation on generic price competition: a review.Pharmacoeconomics. 2010;28(8):649-63. doi: 10.2165/11535360-000000000-00000. Pharmacoeconomics. 2010. PMID: 20515079 Review.
-
Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010.Health Policy. 2012 Aug;106(3):211-24. doi: 10.1016/j.healthpol.2012.04.015. Epub 2012 Jun 12. Health Policy. 2012. PMID: 22694970 Review.
Cited by
-
A Human Rights Case Study on Access to Pre-exposure Prophylaxis for Female Sex Workers in South Africa.Health Hum Rights. 2022 Jun;24(1):105-115. Health Hum Rights. 2022. PMID: 35747274 Free PMC article.
-
Implementation of medicines pricing policies in sub-Saharan Africa: systematic review.Syst Rev. 2022 Dec 1;11(1):257. doi: 10.1186/s13643-022-02114-z. Syst Rev. 2022. PMID: 36457058 Free PMC article.
-
Evidence on the effectiveness of policies promoting price transparency - A systematic review.Health Policy. 2023 Aug;134:104681. doi: 10.1016/j.healthpol.2022.11.002. Epub 2022 Nov 8. Health Policy. 2023. PMID: 36372608 Free PMC article.
-
Implementation of Medicines Pricing Policies in Ghana: The Interplay of Policy Content, Actors' Participation, and Context.Int J Health Policy Manag. 2023;12:7994. doi: 10.34172/ijhpm.2023.7994. Epub 2023 Oct 11. Int J Health Policy Manag. 2023. PMID: 38618785 Free PMC article.
-
Powers, engagements and resultant influences over the design and implementation of medicine pricing policies in Ghana.BMJ Glob Health. 2022 May;7(5):e008225. doi: 10.1136/bmjgh-2021-008225. BMJ Glob Health. 2022. PMID: 35589156 Free PMC article.
References
-
- Carone G, Schwierz C, Xavier A. Cost-containment policies in public pharmaceutical spending in the EU [Internet]. Economic and Financial Affairs. 2012. Available from: 10.2765/27111 - DOI
-
- Aitken M, Machin C, Troein P. Understanding the pharmaceutical value chain. Pharm Policy Law [Internet]. 2016;18(1–4):55–66. Available from: http://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/PP...
-
- Council for Medical Schemes. CMS Annual Report 1995 [Internet]. 1995. Available from: https://www.medicalschemes.com/files/Annual Reports/CMS Annual Report 1995.pdf
-
- National Department of Health South Africa. National Drug Policy for South Africa Table of contents. 1996.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources